Ulipristal acetate

Adverse effect

Biology

Surgery

Uterine leiomyoma

Urology

Leiomyoma

Environmental health

Radiology

Placebo

Alternative medicine

Genetics

Family planning

Population

Internal medicine

Clinical endpoint

Obstetrics

Tolerability

Gynecology

Medicine

Gastroenterology

Randomized controlled trial

Pregnancy

Research methodology

Pathology

Amenorrhea

Obstetrics and Gynecology

OBJECTIVE: To assess efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of symptomatic uterine leiomyomas. METHODS: This phase 3, double-blind, placebo-controlled study enrolled premenopausal women (aged 18–50 years) with abnormal uterine bleeding, one or more discrete leiomyomas, and uterine size 20 weeks of gestation or less. Patients were randomized 1:1:1 to 5 mg ulipristal, 10 mg ulipristal, or placebo once daily for 12 weeks followed by 12-week drug-free follow-up. Coprimary endpoints were rate of and time to amenorrhea, defined as no bleeding for the last 35 consecutive days of treatment. Secondary endpoints included rates of amenorrhea from day 11 and change from baseline to endpoint in the Revised Activities subscale of the Uterine Fibroid Symptom and Quality of Life questionnaire, which includes questions pertaining to physical and social activities. Safety assessments included adverse event monitoring and endometrial biopsies. A sample size of 150 was planned to compare separately each dose of ulipristal with placebo. RESULTS: From March 2014 to March 2016, 157 patients were randomized. Demographics were similar across treatment groups. Amenorrhea was achieved by 25 of 53 (47.2% [97.5% CI 31.6–63.2]) and 28 of 48 (58.3% [97.5% CI 41.2–74.1]) patients treated with 5 mg and 10 mg ulipristal, respectively, compared with 1 of 56 (1.8% [97.5% CI 0.0–10.9]) placebo-treated patients (both P &lt;.001). Time to amenorrhea was shorter for both ulipristal doses compared with placebo ( P &lt;.001), and both doses of ulipristal resulted in improved quality of life compared with placebo ( P &lt;.001). Common adverse events (5% or greater in either ulipristal group during treatment) were hypertension, elevated blood creatinine phosphokinase, and hot flushes. Serious adverse events occurred in four patients, but none was considered related to treatment. Endometrial biopsies were benign. CONCLUSION: Ulipristal at 5 mg and 10 mg were well tolerated and superior to placebo in rate of and time to amenorrhea in women with symptomatic uterine leiomyomas. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov number, NCT02147197.

Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas